6:01 PM
 | 
Sep 17, 2013
 |  BC Extra  |  Clinical News

Somatuline Autogel meets in Phase III for carcinoid syndrome

Ipsen Group (Euronext:IPN; Pink:IPSEY) said subcutaneous Somatuline Autogel every four weeks met the primary endpoint in the Phase III ELECT trial to control symptoms in neuroendocrine tumor patients with a history of carcinoid...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >